Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
Recent years have witnessed notable advances in the management of intermediate and advanced hepatocellular carcinoma (HCC). However, several questions remain unanswered, including the timely transition from locoregional to systemic therapies and the lack of data on sequencing. In this Commentary, we...
Na minha lista:
| 主要作者: | |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Elsevier
2021-12-01
|
| 叢編: | Translational Oncology |
| 主題: | |
| 在線閱讀: | http://www.sciencedirect.com/science/article/pii/S1936523321002382 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|